Human kinome drug discovery and the emerging importance of atypical allosteric inhibitors

Bibliography

• Carter C, Kane C. Therapeutic potential of natural compounds that regulate the activity of protein kinase C. Curr Med Chem 2004;11:2883-902
   PubMed Web of Science ®Google Scholar
• Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547-66
   PubMed Web of Science ®Google Scholar
• Cohen P. Protein kinases – the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1:309-15
   PubMed Web of Science ®Google Scholar
• Ghosh S, Liu X-P, Zheng Y, Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents. Curr Cancer Drug Targets 2001;1:129-40
   PubMed Web of Science ®Google Scholar
• Manning G, Whyte DB, Martinez R, The protein kinase complement of the human genome. Science 2002;298:1912-234
   PubMed Web of Science ®Google Scholar
• Cohen P. The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture. Eur J Biochem 2001;268:5001-10
   PubMedGoogle Scholar
• Nestler E, Greengard P. Protein phosphorylation in the brain. Nature 1983;305:583-8
   PubMed Web of Science ®Google Scholar
• Uckun F, Mao C. Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia. Curr Pharm Des 2004;10:1083-91
   PubMed Web of Science ®Google Scholar
• Knuutila S, Bjorkqvist AM, Autio K, DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Path 1998;152:1107-23
   PubMed Web of Science ®Google Scholar
• Noble M, Endicott J, Johnson L. Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800-5
   PubMed Web of Science ®Google Scholar
• Dancy J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;2:296-313
   PubMed Web of Science ®Google Scholar
• DiGiovanna MP, Stern DF, Edgerton SM, Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients J Clin Oncol 2005;23:1152-1160
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart M, Procter M, Leyland-Jones B, Herceptin Adjuvant (HERA) Trial Study Team. N Engl J Med 2005;353:1659-72
   PubMed Web of Science ®Google Scholar
• Druker B, Tamura S, Buchdunger E, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6
   PubMed Web of Science ®Google Scholar
• Druker B, Talpaz M, Resta D, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7
   PubMed Web of Science ®Google Scholar
• Barker AJ, Gibson KH, Grundy W, Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911-4
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Eckhardt SG. Matrix metalloproteinase inhibitors: how can we optimize their development? Ann Oncol 2001;12:285-7
   PubMed Web of Science ®Google Scholar
• Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy Trends Mol Med 2002; 8:S14-18
   PubMed Web of Science ®Google Scholar
• Eglen RM, Reisine T. The current status of drug discovery against the human kinome. Assays Drug Dev Technol 2009;7:22-43
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang P, Gray N. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39
   PubMed Web of Science ®Google Scholar
• Li B, Liu Y, Uno T, Gray N. Creating chemical diversity to target protein kinases. Comb Chem High Throughput Screen 2004;7(5):453-72
   PubMed Web of Science ®Google Scholar
• Walker E, Pacold M, Perisic O, Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine Mol Cell 2000;6:909-919
   PubMed Web of Science ®Google Scholar
• Blackwell LJ, High-throughput screening of the cyclic AMP-dependent protein kinase (PKA) Using the Caliper microfluidic platform. Methods Mol Biol 2009;565:225-37
   PubMedGoogle Scholar
• Hacker C, In-house kinase selectivity profiling using microfluidics. Available from: http://www.caliperls.com/assets/017/7525.pdf
   Google Scholar
• Comess KM, Kinase drug discovery by affinity selection/mass spectrometry (ASMS): application to DNA damage checkpoint kinase Chk1. J Biomol Screen 2006;11:755-64
   PubMed Web of Science ®Google Scholar
• Nagar B, Bornmann WG, Pellicena P, Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Research, 2002;62:4236-4243
   PubMed Web of Science ®Google Scholar
• Nagar B. Cancer Drug Imatinab (Gleevec/STI-571). J Nutr 2007;137:1518S-23S
   PubMed Web of Science ®Google Scholar
• Lee GM, Craik CS. Trapping moving targets with small molecules. Science 2009;324:213-5
   PubMed Web of Science ®Google Scholar
• Simard JR. et al. Development of a fluorescent tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. JACS 2009;131:13286-96
   PubMed Web of Science ®Google Scholar
• Simard JR, A new screening assay for allosteric inhibitors of cSrc. Nat. Chem Biol 2009;5:394-6
   Google Scholar
• Shen G. Selective protein kinase C inhibitors and their applications. Curr Drug Targets Cardiovasc Haematol Disord 2003;3:301-7
   PubMedGoogle Scholar
• Kim C, Cheng C Y, Saldanha SA, Taylor SS. PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation. Cell 2007;130:1032-43
   PubMed Web of Science ®Google Scholar
• Karin M, Yamamoto Y, Wang Q. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26
   PubMed Web of Science ®Google Scholar
• May M, Ghosh S. IκB kinases: kinsmen with different crafts. Science 1999;284:271-3
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71
   PubMed Web of Science ®Google Scholar
• Haefner B. NF-κB: arresting a major culprit in cancer. Drug Discov Today 2002;7:653-63
   PubMed Web of Science ®Google Scholar
• Karin M, Lin A. NF-κB at the crossroads of life and death. Nature Immunol 2002;3:221-7
   PubMed Web of Science ®Google Scholar
• May M, D'Acquisto F, Madge L, Selective inhibition of NFκB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex. Science 2000;289:1550-4
   PubMed Web of Science ®Google Scholar
• Burke JR, BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. J Biol Chem 2003;278:1450-6
   PubMed Web of Science ®Google Scholar
• Gillooly KM, Periodic, partial inhibition of IKKbeta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis. JPET 2009. Published on August 3, 2009 as doi: 10.1124/jpet.109.156018
   Google Scholar
• Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharm Sci 2002;23:417-25
   PubMed Web of Science ®Google Scholar
• Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008;29:16-21
   PubMed Web of Science ®Google Scholar
• Jeffrey P, Tong L, Pavletich N. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. Genes Dev 2000;14:3115-25
   PubMed Web of Science ®Google Scholar
• Marsden B, Knapp S. Doing more than just the structure-structural genomics in kinase drug discovery. Curr Opin Chem Biol 2008;12:40-5
   PubMed Web of Science ®Google Scholar
• Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors J Mol Biol 1999;287:821-828
   PubMed Web of Science ®Google Scholar
• Parry D, Bates S, Mann DJ, Peters G. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J 1995;14:503-11
   PubMed Web of Science ®Google Scholar
• Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108
   PubMed Web of Science ®Google Scholar
• Zuo L, Weger J, Yang Q, Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-9
   PubMed Web of Science ®Google Scholar
• Adrian FJ, Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006;2:95-102
   PubMed Web of Science ®Google Scholar
• Lindsley CW, The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors [review]. Curr Cancer Drug Targets 2008;8(1):7-18
   PubMed Web of Science ®Google Scholar
• Bogoyevitch MA, Fairlie DP. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting the ATP binding site. Drug Discov Today 2007;12(15-16):622-33
   PubMed Web of Science ®Google Scholar
• El Abdellaoui H, Varaprasad CV, Barawkar D, Identification of isothiazole-4-carboxamidine derivative as a novel class of allosteric MEK1 inhibitors. Bioorg Med Chem Lett 2006;16:5561-6
   PubMed Web of Science ®Google Scholar
• Mussmann R, Geese M, Harder F, Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J Biol Chem 2007;282:12030-7
   PubMed Web of Science ®Google Scholar
• Vassilev LT, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8
   PubMed Web of Science ®Google Scholar
• Haupt Y, Maya R, Kazaz A, Mdm2 promotes rapid degradation of p53. Nature 1997;387:296-9
   PubMed Web of Science ®Google Scholar
• Domling A. Small molecular weight protein–protein interaction antagonists–an insurmountable challenge? Current Opinion in Chemical Biology 2008;12:1-11
   PubMedGoogle Scholar
• Best JL, Amezcua CA, Mayr B, Identification of small molecule antagonists that inhibit an activator: coactivator interaction. Proc Natl Acad Sci USA 2004;101:17622-7
   PubMed Web of Science ®Google Scholar
• Converso A, Hartingh T, Garbaccio RM, Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg Med Chem Lett 2009;19:1240-4
   PubMed Web of Science ®Google Scholar
• Han S, Zhou V, Pan S, Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors. Bioorg Med Chem Lett 2005;15:5467-73
   PubMed Web of Science ®Google Scholar
• Schroter T, Minond D, Weiser A, Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of Rho-kinase II (ROCK-II). J Biomol Screen 2008;13:17-28
   PubMed Web of Science ®Google Scholar
• Braunwalder AF, Yarwood DR, Sills MA, Lipson KE. Measurement of the protein tyrosine kinase activity of c-src using time-resolved fluorometry of europium chelates. Anal Biochem 1996;238:159-64
   PubMed Web of Science ®Google Scholar
• Olive DM. Quantitative methods for the analysis of protein phosphorylation in drug development. Expert Rev Proteomics 2004;1:327-41
   PubMed Web of Science ®Google Scholar
• Zhang WG, Shor B, Yu K. Identification and characterization of a constitutively T-loop phosphorylated and active recombinant S6K1: expression, purification, and enzymatic studies in a high capacity non-radioactive TR-FRET Lance assay. Protein Expr Purif 2006;46:414-20
   PubMed Web of Science ®Google Scholar
• Rodems SM, Hamman BD, Lin C, A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. Assay Drug Dev Technol 2002;1:9-19
   PubMed Web of Science ®Google Scholar
• Mathis G. HTRF(R) technology. J Biomol Screen 1999;4:309-14
   PubMed Web of Science ®Google Scholar
• Rushe M, Silvian L, Bixler S, Structure of a NEMO/IKK-associating domain reveals architecture of the interaction site. Structure 2008;16:798-805
   PubMed Web of Science ®Google Scholar
• Warner G, Illy C, Pedro L, AlphaScreen kinase HTS platforms Curr Med Chem, 2004;11:721-730
   PubMed Web of Science ®Google Scholar
• Chen T, Kablaoui N, Little J, Identification of small-molecule inhibitors of the JIP-JNK interaction. Biochem J 2009;420:283-94
   PubMed Web of Science ®Google Scholar
• Gupta S, Barrett T, Whitmarsh AJ, Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996;15:2760-70
   PubMed Web of Science ®Google Scholar
• Manning A, Davis R. Targeting JNK for therapeutic benefit: from junk to gold? Nat Drug Discov 2003;2:554-65
   PubMed Web of Science ®Google Scholar
• Bennett B, Sasaki D, Murray B, SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001;98:13681-6
   PubMed Web of Science ®Google Scholar
• Hirosumi J, Tuncman G, Chang L, A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-6
   PubMed Web of Science ®Google Scholar
• Seethala R, Menzel R. A fluorescence polarization competition immunoassay for tyrosine kinases. Anal Biochem 1998;255:257-62
   PubMed Web of Science ®Google Scholar
• Fedorov O, Marsden B, Pogacic V, A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. PNAS 2007;104:20523-8
   PubMed Web of Science ®Google Scholar
• Prinz A, Diskar M, Herberg FW. Application of bioluminescence resonance energy transfer (BRET) for biomolecular interaction studies. Chembiochem 2006;7:1007-1012
   PubMed Web of Science ®Google Scholar
• Stefan E, Aquin S, Berger N, Quantification of dynamic protein complexes using Renilla luciferase fragment complementation applied to protein kinase A activities in vivo. Proc Natl Acad Sci USA 2007;104:16916-21
   PubMed Web of Science ®Google Scholar
• Fujioka A, Terai K, Itoh R, Dynamics of the Ras/ERK MAPK cascade as monitored by fluorescent probes. J Biol Chem 2006;281:8917-26
   PubMed Web of Science ®Google Scholar
• Remy I, Michnick S. Clonal selection and in vivo quantitation of protein interactions with protein-fragment complementation assays. Proc Natl Acad Sci USA 1999;96:5394-9
   PubMed Web of Science ®Google Scholar
• Perillan P, Chen M, Potts E, Simard J. Transforming growth factor-beta 1 regulates Kir2.3 inward rectifier K + channels via phospholipase C and protein kinase C-delta in reactive astrocytes from adult rat brain. J Biol Chem 2002;277:1974-80
   PubMed Web of Science ®Google Scholar
• Majumder P, Mishra N, Sun X, Targeting of protein kinase C delta to mitochondria in the oxidative stress response. Cell Growth Differ 2001;9:465-70
   Google Scholar
• O'Flaherty J, Chadwell BA, Kearns MW, Protein kinases C translocation responses to low concentrations of arachidonic acid. J Biol Chem 2001;276:24743-50
   PubMed Web of Science ®Google Scholar
• Gasparri F, Sola F, Bandiera T, High-content analysis of kinase activity in cells. Comb Chem High throughput Screen 2008;11:523-36
   PubMed Web of Science ®Google Scholar
• Palo K, Brand L, Eggeling C, Fluorescence intensity and lifetime distribution analysis: toward higher accuracy in fluorescence fluctuation spectroscopy. Biophys J 2002;83:605-18
   PubMed Web of Science ®Google Scholar
• Trask OJ, Nickischer D, Burton A, High-throughput automated confocal microscopy imaging screen of a kinase-focused library to identify p38 mitogen-activated protein kinase inhibitors using the GE InCell 3000 analyzer. Methods Mol Biol 2009;565:159-86
   PubMedGoogle Scholar
• Almholt DL, Loechel F, Nielsen SJ, Nuclear export inhibitors and kinase inhibitors identified using a MAPK-activated protein kinase 2 redistribution screen. Assay Drug Dev Technol 2004;2:7-20
   PubMed Web of Science ®Google Scholar
• Wolff M, Haasen D, Merk S, Automated high content screening for phosphoinositide 3 kinase inhibition using an AKT1 redistribution assay. Comb Chem High Throughput Screen 2006;9:339-50
   PubMed Web of Science ®Google Scholar
• Michnick SW, MacDonald ML, Westwick JK. Chemical genetic strategies to delineate map kinase signaling pathways using protein fragment complementation assays (PCA). Methods 2006;40:287-93
   PubMed Web of Science ®Google Scholar
• Gallegos L, Kunkel M, Newton A. Targeting protein kinase C activity reporter to discrete intracellular regions reveals spatiotemporal differences in agonist-dependent signaling. J Biol Chem 2006;281:30947-56
   PubMed Web of Science ®Google Scholar
• Corbin A, La Rosee P, Stoffregen E, Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003;101:4611
   PubMed Web of Science ®Google Scholar
• Gorre M, Mohammed M, Ellwood K, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876
   PubMed Web of Science ®Google Scholar
• Eglen R, Gilchrist A, Reisine T. An overview of high throughput screening using primary and embryonic stem cells. Comb Chem High Throughput Screen 2008;11:566-72
   PubMed Web of Science ®Google Scholar
• Eglen R, Reisine T. New insights into GPCR function: implications for HTS [review]. Methods Mol Biol 2009;552:1-13
   PubMedGoogle Scholar